TIM

Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. U.S. Serial No. 10/729,167 Filing Date 04 December 2003 TRANSMITTAL Applicant(s) Fourney et al. **FORM** Art Unit (to be used for all correspondence after initial filing) **Examiner Name** Not yet assigned Docket No. FP0602.2 US **ENCLOSURES** (Check all that apply) After Allowance Communication X Drawing(s) Fee Transmittal Form Appeal Communication to Board Licensing-related Papers of Appeals and Interferences Fee Attached Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Petition Amendment/Reply Petition to Convert to a **Proprietary Information Provisional Application** After Final Power of Attorney, Revocation Status Letter Change of Correspondence Address Affidavits/declaration(s) Other Enclosure(s) (please **Terminal Disclaimer** Identify below): Extension of Time Request FORM PTO/SB/08A (2 pages). Request for Refund Copies of 28 cited references. Express Abandonment Request CD, Number of CD(s) X Information Disclosure Statement Remarks Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Christopher Turner, Ph.D. Individual Signature Date 22 July 2004 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450 on this date: 22 July 2004 Carolyn C. Caires Typed or printed Date DaJuly 200

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

lall

Signature

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 22 July 2004. Approved for use through 07/31/2006. OMB 0651-0032 100000CC U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Carolyn C. Caires Complete if Known **RANSMITTAL** 10/729,167 Application Number 4 December 2003 Filing Date for FY 2004 **2004** Fourney et al. в First Named Inventor W 10/01/2003. Patent fees are subject to annual revision. ERRENT & Not yet assigned Effective: **Examiner Name** 1641 Apple ant claims small entity status. See 37 CFR 1.27 X Art Unit FP0602.2 US 0 Attorney Docket No. TOTAL AMOUNT OF PAYMENT FEE CALCULATION (continued) METHOD OF PAYMENT (check all that apply) 3. ADDITIONAL FEES Money Order Other None Check Credit card arge Entity | Small Entity **Fee Description** Deposit Account: Fee Fee <u>Fee Paid</u> Code (\$) Code (\$) Deposit 50-0811 65 Surcharge - late filing fee or oath 2051 Account 1051 130 Surcharge - late provisional filing fee or Number 2052 25 1052 50 Deposit cover sheet FibroGen, Inc. Account Non-English specification 130 130 1053 1053 Name The Director is authorized to: (check all that apply) 1812 2,520 For filing a request for ex parte reexamination 1812 2,520 Credit any overpayments Charge fee(s) indicated below 920\* Requesting publication of SIR prior to 920 1804 1804 Charge any additional fee(s) or any underpayment of fee(s) Examiner action Requesting publication of SIR after Charge fee(s) indicated below, except for the filing fee 1805 1.8401 1805 1,840 Examiner action to the above-identified deposit account Extension for reply within first month 110 2251 55 1251 Extension for reply within second month **FEE CALCULATION** 210 420 2252 1252 1. BASIC FILING FEE 475 Extension for reply within third month 950 2253 1253 arge Entity Small Entity Extension for reply within fourth month Fee Paid 740 1,480 2254 Fee Description 1254 ee Fee Code (\$) Fee\_ Fee Fee Code (\$) 1,005 Extension for reply within fifth month 2,010 2255 1255 Utility filing fee 2001 385 1001 770 165 Notice of Appeal 330 2401 1401 Design filing fee 2002 170 1002 340 165 Filing a brief in support of an appeal 2402 330 1402 2003 265 Plant filing fee 1003 530 145 Request for oral hearing 2403 1403 290 Reissue filing fee 2004 385 1004 770 1,510 Petition to institute a public use proceeding 1451 1451 1.510 Provisional filing fee 2005 80 1005 160 55 Petition to revive - unavoidable 2452 110 1452 0 SUBTOTAL (1) (\$) 665 Petition to revive - unintentional 1453 1,330 2453 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE 665 Utility issue fee (or reissue) 2501 1501 1,330 240 Design issue fee 2502 Fee Paid 1502 480 Extra Claims below ō 320 Plant issue fee 640 2503 1503 Total Claims -20\*\* = 0 130 Petitions to the Commissioner Independent 1460 1460 130 50 Processing fee under 37 CFR 1.17(q)  $\overline{0}$ Multiple Dependent 50 1807 1807 180 Submission of Information Disclosure Stmt 1806 1806 180 40 Recording each patent assignment per Large Entity | **Small Entity** Fee Description Fee Fee Code (\$) Fee 8021 40 8021 property (times number of properties) Code (\$) 385 Filing a submission after final rejection (37 CFR 1.129(a)) Claims in excess of 20 9 2202 2809 1202 18 1809 770 Independent claims in excess of 3 2201 43 1201 86 385 For each additional invention to be Multiple dependent claim, if not paid 770 1810 2810 2203 145 1203 290 examined (37 CFR 1.129(b)) \*\* Reissue independent claims Request for Continued Examination (RCE) 2204 43 1204 86 770 2801 385 1801 over original patent Request for expedited examination 900 900 1802 \*\* Reissue claims in excess of 20 2205 9 of a design application 1205 18 and over original patent Other fee (specify) 0 (\$) 0 SUBTOTAL (2) \*Reduced by Basic Filing Fee Paid (\$) SUBTOTAL (3)

\*\*or number previously paid, if greater; For Reissues, see above (Complete (if applicable))

SUBMITTED BY

Name (Print/Type) Christopher Turner, Ph.D.

Signature

Registration No. (Attorney/Agent)
(Attorney/Agent)

Date 12 Tuly 2004

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 22 July 2004. PTO/SB/17 (10-03) Approved for use through 07/31/2006. OMB 0651-0032 mohr) U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Carolyn C. Caires Complete if Known TRANSMITTAL 10/729,167 Application Number 4 December 2003 Filing Date for FY 2004 500r Fourney et al. First Named Inventor 1 JUL tive 10/01/2003. Patent fees are subject to annual revision. Not yet assigned **Examiner Name** plicant claims small entity status. See 37 CFR 1.27 1641 Art Unit FP0602.2 US Attorney Docket No. TOTAL AMOUNT OF PAYMENT (\$) FEE CALCULATION (continued) METHOD OF PAYMENT (check all that apply) 3. ADDITIONAL FEES Money Order Other None Check Credit card arge Entity , Small Entity Deposit Account: Fee Fee Description Fee Fee Paid Code Code (\$) Deposit 50-0811 65 Surcharge - late filing fee or oath 2051 130 Account 1051 Number 25 Surcharge - late provisional filing fee or 50 2052 1052 Deposit cover sheet FibroGen, Inc. Account 130 Non-English specification 1053 130 1053 Name The Director is authorized to: (check all that apply) 1812 2,520 For filing a request for ex parte reexamination 1812 2,520 Credit any overpayments Charge fee(s) indicated below 920\* Requesting publication of SIR prior to 1804 1804 920 K Charge any additional fee(s) or any underpayment of fee(s) Examiner action Requesting publication of SIR after Charge fee(s) indicated below, except for the filing fee 1805 1,840\* 1805 1,840 Examiner action to the above-identified deposit account Extension for reply within first month 110 2251 1251 Extension for reply within second month **FEE CALCULATION** 2252 210 1252 420 1. BASIC FILING FEE Extension for reply within third month 950 2253 1253 arge Entity Small Entity Extension for reply within fourth month Fee Paid 740 Fee Description 1254 1,480 2254 1,005 Extension for reply within fifth month Code (\$) Code (\$) 1255 2,010 2255 Utility filing fee 2001 385 1001 770 165 Notice of Appeal 2401 1401 330 Design filing fee 2002 170 1002 340 165 Filing a brief in support of an appeal 2402 1402 330 2003 265 Plant filing fee 1003 530 145 Request for oral hearing 2403 1403 290 Reissue filing fee 2004 385 1004 770 1,510 Petition to institute a public use proceeding 1451 1451 1.510 Provisional filing fee 2005 80 1005 160 55 Petition to revive - unavoidable 2452 1452 110 SUBTOTAL (1) (\$) 665 Petition to revive - unintentional 2453 1453 1,330 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE 665 Utility issue fee (or reissue) 1,330 2501 1501 240 Design issue fee 480 2502 Fee Paid 1502 Extra Claims below 0 320 Plant issue fee 2503 640 **Total Claims** Х 1503 0 130 Petitions to the Commissioner Independent 130 1460 1460 50 Processing fee under 37 CFR 1.17(q) Multiple Dependent 1807 50 1807 180 Submission of Information Disclosure Stmt 1806 Large Entity ( 180 Small Entity 1806 40 Recording each patent assignment per Fee Description Fee Fee Fee 8021 property (times number of properties) 8021 40 Code (\$) Code (\$) 385 Filling a submission after final rejection (37 CFR 1.129(a)) Claims in excess of 20 1202 18 2202 9 770 2809 1809 Independent claims in excess of 3 2201 43 1201 86 385 For each additional invention to be 770 2810 Multiple dependent claim, if not paid 1810 examined (37 CFR 1.129(b)) 1203 290 2203 145 \*\* Reissue independent claims 385 Request for Continued Examination (RCE) 43 2204 86 1204 2801 770 1801 over original patent 900 Request for expedited examination 1802 900 1802 \*\* Reissue claims in excess of 20 2205 9 of a design application 1205 18

**	SUBTOTAL (2) (\$) 0 y paid, if greater; For Reissues, see above	Other fee (specify) *Reduced by Basic Filing	g Fee Paid	SUBTOTAL	(3) (\$) 0
	y paid, ii grouter, i di vicina			(Complete (ii	f applicable))
SUBMITTED BY	Christopher Turner, Ph.D.	Registration No. (Attorney/Agent)	45,167	Telephone	650-866-7200
Name (Print/Type)	Char.	(AROMEV/Agent)		Date	22 July 2004
Signature	Oro par	any become nublic. Cr	edit card info	rmation shou	ld not

and over original patent

WARNING: Information on this form may become public. Credit card Information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Printed: Carolyn C. Caires

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Fourney et al.

Title:

**FAT REGULATION** 

U.S. Serial No.:

10/729,167

Filing Date:

04 December 2003

Examiner:

Not yet assigned

Group Art Unit:

1641

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97(b)

Sir:

Pursuant to 37 C.F.R. 1.56, 1.97, and 1.98, Applicants wish to call to the attention of the Examiner the enclosed, "List of References Cited by Applicants" (Form PTO/SB/08A).

Applicants reserve the right to antedate any reference in accordance with standard procedure.

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the present application. In addition, this submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made or that the cited items are inclusive of all the relevant and material citations that may be available publicly. Any NCBI or other report included on the attached list may not have an accurate date for prior art purposes. Some of the documents may have markings thereon. No significance is meant to be

attached to the markings. Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the Form PTO/SB/08A be returned to Applicants.

If there are any questions regarding this communication, please call the undersigned at 650-866-7200.

Applicants believe that no fee is due with this communication. If, however, the Commissioner determines that a fee is due, the Commissioner is hereby authorized to charge any necessary fees, or credit any overpayment, to **Deposit Account No. 50-0811**. This form is enclosed in duplicate.

Respectfully submitted, FibroGen, Inc.

DATE: 22 July 2004

Christopher Turner, Ph.D.

Reg. No. 45,167

FibroGen, Inc. 225 Gateway Boulevard South San Francisco CA 94080

Main: 650-866-7200 Direct: 650-866-7265 Facsimile: 650-866-7204

							U.S. Serial	No.	10/729,167	7	
5E	NIFORMATION DISCLOSURE						Filing Date		4 December	er 2003	
ILE N	STATEMENT BY APPLICANT							111118		Fourney et al.	
and I	List of References Cited by Applicants)								1641		
INT S & SOME	STATEMENT BY APPLICANT  Of References Cited by Applicants)				Group Art Unit						
J.					Examiner Name Not yet ass						
Sheet	of 2						Docket No		FP0602.2	US	
Stephen 1	<u> </u>			U.S	. PAT	ENT D	<b>OCUMEN</b>				
EXAMINER	CITE	U.S.	PATENT DOCUME			ME OF PAT	TENTEE OR		UBLICATION DOCUMENT	PAGES, COLUMNS, LINES, WHERE RELEVANT	
INITIALS*	NO.	Number Kind Code (if known)			APPLICANT OF CITED DOCUMENT			4 March 1997		PASSAGES OR RELEVANT FIGURES APPEAR	
	1	5,607,954			Weidmann et al. Weidmann et al.		11 March 1997				
	2	5,610	,172								
• . : _	3	5,620	,995			lmann e		15 April			
	4	5,620	,996		Weidmann et al.		15 April 1997				
	5	5,658	,933		-	dmann e		19 April 1997 17 February 1998			
	6	5,719	,164			dmann (					
•	7	5,726				dmann		10 Marcl			
	8	5,916	5,898			ards et		29 June			
•	9	5,942			Ratcliffe et al. Weidmann et al.		24 Augu				
	10	6,020					1 Februa 25 July 2	<u> </u>			
	11	6,093		Weidmann et al.				mber 2000			
	12	6,124			Semenza et al.  B1 Edwards et al.		13 Marc				
	13	6,200		<del> </del>			13 Augu				
	14	6,432		B1		gory et	13 May 2				
	15	6,562	2,799	B1		nenza	T DOCUM		2003		
		1 707	STICN DATENT DO			PAIL!	NT DOCUMPATENTEE OR	DATE OF	PUBLICATION	PAGES, COLUMNS,	
EXAMINER INITIALS*	CITE NO.	FOREIGN PATENT DOCUM Office Number Kind (if k			ie	APPLICA	NT OF CITED CUMENT		DOCUMENT	LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	
	16	wo	02/074981	A	2 I	sis Inno	vation Ltd.	26 Septe	ember 2002		
	17	WO	03/045440	F		Angioge Sweden		5 June 2	.003	·	
	18	wo	03/049686	I	\2 F	FibroGe	n, Inc.	19 June	2003		
	19	wo	03/080566	$ {\vdash}$	12 I	sis Inno	vation Ltd.	2 Octob	er 2003		
	20	WO	99/21860	T A		FibroGe Zeneca	en, Inc. Limited	6 May 1			
	21	EP	0 650 961		31 I	Hoechst		5 Marcl	ı 1997		
EXAMI	NER						E CONSIDI	ERED			
	•					1					

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

				U.S. Serial No.	10/729,167				
			DRMATION DISCLOSURE	Filing Date	4 December 2003				
			TEMENT BY APPLICANT	Applicant(s)	Fourney et al.				
(List of References Cited by Applicants)				Group Art Unit	To be assigned				
				Examiner Name	To be assigned				
Sheet	2.	of 2		Docket No.	FP0602.2 US				
Blicct		<u> </u>	OTHER PRIOR ART - NON PATE	ENT LITERATURE D	OCUMENTS				
EXAMIN	ER	Cite ·				T			
MITIAL	ALS* No								
		22							
•		23	Epstein et al. (2001) Cell 107:43-54.						
		24	Fushiki et al. (1992) Can J Physiol Pharmacol 70:1522-1524.						
		25	Gunga et al. (2003) Eur J Appl Physiol 88:497-505.						
		26	Ivan et al. (2001) Science 292:464-468.						
<u>-</u>		27	Jaakkola et al. (2001) Science 292:468-472.						
Į*		28	Srinivas et al. (1999) Biochem Biophys Res Commun 260:557-561.						
		<u> </u>							
		ļ				-			
			12.47	TE CONSIDERED		<u> </u>			
EXAN	MINI	ER	DAI	E CONSIDERED					
				C	ED Section 600: Draw line through cita	tion			

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.